摘要
目的:探究左归丸、富血小板血浆(PRP)、间充质干细胞(MSCs)三联疗法对膝骨关节炎患者的治疗效果及对患者血清骨形态发生蛋白-2(BMP-2)、软骨寡聚基质蛋白(COMP)与血清炎症因子[白细胞介素-6(IL-6)、白细胞介素-17(IL-17)、C反应蛋白(CRP)水平]的影响。方法:选取2022年4月—2023年1月在新余市人民医院接受治疗的98例膝骨关节炎患者,按照随机抽签法将患者分入对照组和观察组,各49例。对照组接受膝骨关节炎的常规治疗,观察组在此基础上加用左归丸、PRP、MSCs三联疗法。对两组治疗前后中医证候积分、奎森功能演算指数(Lequesne)、西安大略和麦克马斯特大学骨关节炎指数(WOMAC)评分、BMP-2、COMP、IL-6、IL-17、CRP水平、疗效进行对比。结果:治疗后,与对照组相比,观察组中医证候各项积分、Lequesne评分、WOMAC评分、COMP、IL-6、IL-17、CRP水平均较低(P<0.05),BMP-2水平较高(P<0.05),疗效更优(P<0.05)。结论:左归丸、PRP、MSCs三联疗法有良好的治疗效果,可更有效地改善患者膝关节功能,缓解疾病带来的不适,提高患者生活水平。
Objective:To explore the therapeutic effect of Zuogui Pills,platelet-rich plasma(PRP),mesenchymal stem cell(MSCs)triple therapy on patients with knee osteoarthritis and its influence on the levels of serum bone morphogenetic protein-2(BMP-2),cartilage oligomeric matrix protein(COMP)and serum inflammatory factors[interleukin-6(IL-6),interleukin-17(IL-17),C reactive protein(CRP)].Method:A total of 98 patients with knee osteoarthritis treated in Xinyu People's Hospital from April 2022 to January 2023 were selected and divided into control group and observation group according to the random lottery method,with 49 cases in each group.The control group received conventional treatment for knee osteoarthritis,and the observation group was added with Zuogui Pills,PRP,and MSCs triple therapy on this basis.The TCM syndrome score,Lequesne functional index(Lequesne),BMP-2,COMP,Western Ontario and McMaster University Osteoarthritis Index(WOMAC)score,IL-6,IL-17,CRP levels and efficacy of two groups were compared before and after treatment.Result:After treatment,compared with the control group,the scores of TCM syndrome,Lequesne,WOMAC score,COMP,IL-6,IL-17 and CRP levels were lower in the observation group(P<0.05),and the level of BMP-2 was higher(P<0.05),and the curative effect was better(P<0.05).Conclusion:Zuogui Pills,PRP and MSCs triple therapy has good therapeutic effect,which can improve the knee function of patients more effectively,relieve the discomfort brought by the disease and improve the living levels of patients.
作者
袁垒
徐冬梅
丁伟明
YUAN Lei;XU Dongmei;DING Weiming(Department of Pain Rehabilitation,Xinyu People's Hospital,Xinyu 338000,China;不详)
出处
《中国医学创新》
CAS
2024年第25期135-139,共5页
Medical Innovation of China
关键词
膝骨关节炎
软骨寡聚基质蛋白
骨形态发生蛋白-2
左归丸
富血小板血浆
间充质干细胞
Knee osteoarthritis
Cartilage oligomeric matrix protein
Bone morphogenetic protein-2
Zuogui Pills
Platelet-rich plasma
Mesenchymal stem cell
